MedTrace Logo

PF-04995274 and Emotional Processing in Un-medicated Depression

NCT03516604 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-11-03

No results posted yet for this study

Summary

This study will test whether seven days administration of a serotonin receptor subtype 4 (5HT4) agonist called PF-04995274 has positive effects on cognition, emotional processing and neural activity in unmedicated depressed patients compared to placebo. The study will also include a group of patients randomised to seven days administration of citalopram (20 mg), which is a standard treatment for depression.

Conditions

  • Depression, Unipolar

Interventions

DRUG

PF-04995274

PF-04995274 tablets

DRUG

Citalopram

Citalopram capsule

DRUG

Placebo Oral Tablet

Placebo tablet, identical to PF-04995274 tablet

DRUG

Placebo oral capsule

Placebo capsule, identical to citalopram capsule

Sponsors & Collaborators

Principal Investigators

  • Catherine Harmer · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-16
Primary Completion
2022-07-29
Completion
2022-07-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03516604 on ClinicalTrials.gov